Skip to main content
    R

    Rein Therapeutics Inc (RNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.36
    -0.04 (-10.90%)

    Market Cap: $34.51M

    Last updated: Nov 17, 2026 at 4:29 PM ET

    Rein Therapeutics Inc (RNTX) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Rein Therapeutics (RNTX) has a latest price of $0.36 on Nov 17, 2026, 83.0% below its 52-week high of $2.10. Its price fell 71.5% over the past 12 months. The month-end price fell 70.1% over the 10 years through Oct 2026, a compound annual decline of 11.4%.

    Price Chart

    From Oct 2016 to Oct 2026, its highest month-end close was $267.60 in Sep 2017 and its lowest $0.67 in Oct 2026, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart RNTX with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RNTX.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 55.0%, and over 6 months it fell 64.2%. The month-end price fell 42.7% over the 3 years through Oct 2026, a compound annual decline of 17.0%.

    PeriodChange
    1 month-35.4%
    3 months-55.0%
    6 months-64.2%
    12 months-71.5%
    12 months, with dividends-71.5%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years-42.7%-17.0%
    5 years-96.1%-47.9%
    10 years-70.1%-11.4%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2017, when the price rose 9,302.3%, and its weakest was 2018, when it fell 92.0%.

    YearCloseChange
    2026 through Oct 2026$0.67-42.2%
    2025$1.16-49.6%
    2024$2.30-24.6%
    2023$3.05+28.6%
    2022$2.37-78.9%
    2021$11.26-45.9%
    2020$20.80+81.5%
    2019$11.46-31.8%
    2018$16.80-92.0%
    2017$210.80+9,302.3%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 48.5% below its 50-day average of $0.69 and 64.1% below its 200-day average of $0.99.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$0.36
    52-week high$2.10-83.0%
    52-week low$0.28+25.5%
    50-day average$0.69-48.5%
    200-day average$0.99-64.1%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 94.9%.

    MeasureValue
    1-year beta2.38
    Largest fall, 1 year-81.0%
    Largest fall, 3 years-94.9%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About RNTX

    What is RNTX's 1-year price change?

    Rein Therapeutics's price fell 71.5% over the past 12 months. With dividends included, the 12-month total return was -71.5%.

    What is RNTX's 5-year price change?

    Rein Therapeutics's month-end price fell 96.1% over the 5 years through Oct 2026, a compound annual decline of 47.9%. These figures leave out dividends.

    What is RNTX's 52-week high and low?

    Rein Therapeutics's 52-week high is $2.10 and its 52-week low is $0.28. Its latest price of $0.36 on Nov 17, 2026 is 83.0% below the high.

    What is RNTX's beta?

    Rein Therapeutics's 1-year beta against the S&P 500 is 2.38, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 81.0%.

    Is the RNTX chart free?

    Yes. Advanced Charting for RNTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.